Veru AdComm Highlights Differing EUA Philosophies Based On Lingering COVID-19 Deaths

 
• By Sarah Karlin-Smith

In a close but negative panel vote on the company’s acute respiratory distress syndrome treatment VERU-111 (sabizabulin), majority of US FDA advisory committee says more study should come ahead of an emergency use authorization, not as an authorization condition.

diverging paths with arrows
FDA advisors split on whether further study of VERU-111 should come before of after an EUA • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers